EFFICACY AND SAFETY OF DRUG-ELUTING BALLOON VS DRUG-ELUTING STENTS IN THE TREATMENT OF IN-STENT RESTENOSIS

S AYAZ; F AKBAR; U ARA; K HUSSAIN; AM Omer; SRA GILANI

doi:10.54112/bcsrj.v2023i1.453

Authors

S AYAZ Department of Cardiology, Peshawar Institute of Cardiology, Peshawar, Pakistan
F AKBAR Department of Cardiology, Peshawar Institute of Cardiology, Peshawar, Pakistan
U ARA Department of Cardiology, Peshawar Institute of Cardiology, Peshawar, Pakistan
K HUSSAIN College of Pharmacy ISRA University Hyderabad, Sindh, Pakistan
AM Omer Department of Cardiology, Islamic International Medical College, Rawalpindi, Pakistan
SRA GILANI Allama Iqbal Medical College / Jinnah Hospital Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.453

Keywords:

In-Stent Restenosis, Drug-Eluting Balloon, Drug-Eluting Stents, Efficacy

Abstract

The in-stent restenosis (ISR) treatment remains related to the higher recurrence rate. This comparative study aimed to compare the effectiveness and safety of drug-eluting balloon (DEB) vs drug-eluting stents (DES) in the in-stent restenosis treatment.

Sixty-four patients who underwent PCI for ISR in the Department of Cardiology, Peshawar Institute of Cardiology, Peshawar, from October 2022 to March 2023 were enrolled. Patients were distributed as Group-I patients treated with drug-eluting balloons (n=28, 43.8%) and Group-II patients treated with drug-eluting stents (n=36, 56.2%). Clinical outcomes were recorded. Target lesion revascularization (TLR), myocardial infarction, and cardiac death were different endpoints of major adverse cardiac events (MACE). The overall mean age was 64.12±4.65 years. The incidence of MACEs in groups I and II was 14.3% (n=4) and 16.7% (n=6) respectively. Group I and II had insignificant associations regarding baseline characteristics except for MI's prior history. TLR was more frequent in the DEB group (7.1%, n=2) than in the DES group (2.8%, n=1). The incidence of diabetes, hypertension, current smokers, and previous myocardial infarction in Group I vs. Group II was 42.9% vs. 38.9%, 64.3% vs. 47.2%, 14.3% vs. 22.2%, and 17.9% vs. 47.2%, respectively. Drug-eluting balloons showed effective results for PCI, a viable alternative to placing drug-eluting stents for the coronary in-stent restenosis treatment.

Downloads

Download data is not yet available.

References

Adriaenssens, T., Dens, J., Ughi, G., Bennett, J., Dubois, C., Sinnaeve, P., Wiyono, S., Coosemans, M., Belmans, A., and D'hooge, J. (2014). Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 10, 439-448.

Alfonso, F., Byrne, R. A., Rivero, F., and Kastrati, A. (2014a). Current treatment of in-stent restenosis. Journal of the American College of Cardiology 63, 2659-2673.

Alfonso, F., Pérez-Vizcayno, M. J., Cárdenas, A., García del Blanco, B., García-Touchard, A., López-Minguéz, J. R., Benedicto, A., Masotti, M., Zueco, J., and Iñiguez, A. (2015). A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. Journal of the American College of Cardiology 66, 23-33.

Alfonso, F., Pérez-Vizcayno, M. J., Cárdenas, A., García del Blanco, B., Seidelberger, B., Iñiguez, A., Gómez-Recio, M., Masotti, M., Velázquez, M. T., and Sanchís, J. (2014b). A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent–in-Stent restenosis: the RIBS V clinical trial (Restenosis intra-stent of bare metal stents: paclitaxel-eluting Balloon vs. everolimus-eluting Stent). Journal of the American College of Cardiology 63, 1378-1386.

Alfonso, F., Pérez-Vizcayno, M. J., Del Blanco, B. G., García-Touchard, A., López-Mínguez, J.-R., Sabaté, M., Zueco, J., Melgares, R., Hernández, R., and Moreno, R. (2017). Usefulness of drug-eluting balloons for bare-metal and drug-eluting in-stent restenosis (from the RIBS IV and V randomized trials). The American Journal of Cardiology 119, 983-990.

Baan, J., Claessen, B. E., Dijk, K. B.-v., Vendrik, J., van der Schaaf, R. J., Meuwissen, M., van Royen, N., Gosselink, A. M., van Wely, M. H., and Dirkali, A. (2018). A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE trial. JACC: Cardiovascular Interventions 11, 275-283.

Buchanan, K. D., Torguson, R., Rogers, T., Xu, L., Gai, J., Ben-Dor, I., Suddath, W. O., Satler, L. F., and Waksman, R. (2018). In-stent restenosis of drug-eluting stents compared with a matched group of patients with de novo coronary artery stenosis. The American Journal of Cardiology 121, 1512-1518.

Byrne, R., Neumann, F., Mehilli, J., Pinieck, S., Wolff, B., Tiroch, K., Schulz, S., Fusaro, M., Ott, I., and Ibrahim, T. (2013a). ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 381, 461-7.

Byrne, R. A., Cassese, S., Windisch, T., King, L. A., Joner, M., Tada, T., Mehilli, J., Pache, J., and Kastrati, A. (2013b). Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 9, 797-802.

Cassese, S., Byrne, R. A., Schulz, S., Hoppman, P., Kreutzer, J., Feuchtenberger, A., Ibrahim, T., Ott, I., Fusaro, M., and Schunkert, H. (2015). Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. European heart journal 36, 94-99.

Giacoppo, D., Alfonso, F., Xu, B., Claessen, B. E., Adriaenssens, T., Jensen, C., Perez-Vizcayno, M. J., Kang, D.-Y., Degenhardt, R., and Pleva, L. (2020a). Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). European Heart Journal 41, 3715-3728.

Giacoppo, D., Alfonso, F., Xu, B., Claessen, B. E., Adriaenssens, T., Jensen, C., Pérez-Vizcayno, M. J., Kang, D.-Y., Degenhardt, R., and Pleva, L. (2020b). Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. Journal of the American College of Cardiology 75, 2664-2678.

Jensen, C. J., Richardt, G., Tölg, R., Erglis, A., Skurk, C., Jung, W., Neumann, F.-J., Stangl, K., Brachmann, J., and Fischer, D. (2018). Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 14, 1096-1103.

Kufner, S., Joner, M., Thannheimer, A., Hoppmann, P., Ibrahim, T., Mayer, K., Cassese, S., Laugwitz, K.-L., Schunkert, H., and Kastrati, A. (2019). Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: results from the ISAR-TEST 4 randomized trial. Circulation 139, 325-333.

Nakano, M., Otsuka, F., Yahagi, K., Sakakura, K., Kutys, R., Ladich, E. R., Finn, A. V., Kolodgie, F. D., and Virmani, R. (2013). Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. European heart journal 34, 3304-3313.

Oh, P. C., Suh, S. Y., Kang, W. C., Lee, K., Han, S. H., Ahn, T., and Shin, E. K. (2016). The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty. The Korean Journal of Internal Medicine 31, 501.

Pilgrim, T., Piccolo, R., Heg, D., Roffi, M., Tüller, D., Muller, O., Moarof, I., Siontis, G. C., Cook, S., and Weilenmann, D. (2018). Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. The Lancet 392, 737-746.

Pleva, L., Kukla, P., Kusnierova, P., Zapletalova, J., and Hlinomaz, O. (2016). Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the treatment of in-stent restenosis study. Circulation: Cardiovascular Interventions 9, e003316.

Richardt, G., Leschke, M., Abdel-Wahab, M., Toelg, R., El-Mawardy, M., Serruys, P. W., Silber, S., Windecker, S., Belardi, J. A., and Neumann, F.-J. (2013). Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. JACC: Cardiovascular interventions 6, 905-913.

Song, L., Mintz, G. S., Yin, D., Yamamoto, M. H., Chin, C. Y., Matsumura, M., Fall, K., Kirtane, A. J., Parikh, M. A., and Moses, J. W. (2017). Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first-and second-generation drug-eluting stents. The International Journal of Cardiovascular Imaging 33, 1115-1124.

Steinberg, D. H., Gaglia Jr, M. A., Slottow, T. L. P., Roy, P., Bonello, L., De Labriolle, A., Lemesle, G., Torguson, R., Kineshige, K., and Xue, Z. (2009). Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. The American journal of cardiology 103, 491-495.

Unverdorben, M., Vallbracht, C., Cremers, B., Heuer, H., Hengstenberg, C., Maikowski, C., Werner, G. S., Antoni, D., Kleber, F. X., and Bocksch, W. (2009). Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119, 2986-2994.

Wong, Y. T. A., Kang, D.-Y., Lee, J. B., Rha, S.-W., Hong, Y. J., Shin, E.-S., Her, S.-H., Nam, C. W., Chung, W.-Y., and Kim, M. H. (2018). Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: a randomized RESTORE trial. American Heart Journal 197, 35-42.

Xu, B., Gao, R., Wang, J. a., Yang, Y., Chen, S., Liu, B., Chen, F., Li, Z., Han, Y., and Fu, G. (2014). A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC: Cardiovascular Interventions 7, 204-211.